Tamoxifen-Induced Nonalcoholic Steatohepatitis
| Autor: | Hideaki Enzan, Katsumi Toda, Masafumi Ono, Toshiji Saibara, Akihiko Wakatsuki, Saburo Onishi, Yasuhiro Ogawa, Nan Xu, Yoshihisa Nemoto |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
medicine.medical_specialty
Bezafibrate biology medicine.drug_class business.industry Fatty liver Fatty acid beta-oxidation medicine.disease Endocrinology Breast cancer Estrogen Internal medicine medicine biology.protein Steatosis Aromatase skin and connective tissue diseases business hormones hormone substitutes and hormone antagonists Tamoxifen medicine.drug |
| Zdroj: | HCV/Oxidative Stress and Liver Disease ISBN: 9784431670070 |
| DOI: | 10.1007/978-4-431-67005-6_11 |
| Popis: | Tamoxifen is a potent antagonist of estrogen and evidently improves the prognosis of patients with estrogen receptor-positive breast cancer. However, although tamoxifen has been shown to induce hepatic steatosis in one-third of nonobese breast cancer patients, the pathogenic mechanisms have not yet been defined. Impaired fatty acid beta oxidation has been proposed as a possible pathogenic mechanism involved in tamoxifen-induced hepatic steatosis, because fatty acid beta oxidation activity is impaired in aromatase-deficient mice lacking intrinsic estrogen, and because either estradiol supplementation or administration of bezafibrate improved impaired beta oxidation activity to prevent the progression of hepatic steatosis. Previously, we investigated why tamoxifen is such a potent estrogen antagonist and found that the serum estradiol level was extremely low ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|